Lucentis for New Onset Neovascular Glaucoma

Sponsor
University of Illinois at Chicago
Study ID
NCT00727038
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

  • Glaucoma
  • Neovascular Glaucoma
  • New Onset Glaucoma
  • New Onset Neovascular Glaucoma

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Neovascular glaucoma is a potentially debilitating disease of the eye. Vascular eye disease such as diabetes and vein occlusions can cause the retina to release factors that promote the growth of abnormal blood vessels. These abnormal vessels can grow in the drainage mechanism of the eye causing pressure in the eye to markedly increase. This can potentially cause irreversible damage to the optic nerve from glaucoma leading to permanent blindness and painful eyes. Conventional treatments including laser and freezing therapy take weeks to cause regression in abnormal blood vessel growth. This delay often results in permanent vision loss and pain. New medications targeted at more immediately reducing blood vessel growth may aid in the treatment of this disease.

Key Dates

First listed
Aug 1, 2008
Start date
Jan 4, 2008
Status verified
Jul 2008
Primary completion
May 15, 2009
Completion
May 15, 2009

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Lucentis (ranibizumab) with conventional treatment
  • No Intervention: 2
    Conventional treatment

Primary Outcome Measure

Mean change in best corrected visual acuity (BCVA) as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters from baseline to Month 6. [ Time Frame: Baseline to Month 6. ]

Related Studies